New drug combo aims to extend life in rare, aggressive gut cancers
Disease control
Recruiting now
This study tests a drug called tarlatamab, which helps the immune system find and attack cancer cells, in people with advanced neuroendocrine carcinomas of the digestive system or unknown origin. About 87 adults will receive tarlatamab alone or with standard chemotherapy. The goa…
Phase: PHASE2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated May 02, 2026 16:47 UTC